Cytokinetics Inc(CYTK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:00 PM ET (Korea 10/27 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -7.22 | Insider Own | 3.51% | Shs Outstand | 138.8M | Perf Week | -3.06% |
| Market Cap | 8.44B | Forward P/E | - | EPS next Y | 25.04% | Insider Trans | -8.07% | Shs Float | 134.2M | Perf Month | -6.08% |
| Enterprise Value | 8.54B | PEG | - | EPS next Q | -1.44 | Inst Own | 113.24% | Short Float | 14.41% | Perf Quarter | -23.56% |
| Income | -0.89B | P/S | 124.76 | EPS this Y | 7.85% | Inst Trans | 10.68% | Short Ratio | 9.88 | Perf Half Y | -1.41% |
| Sales | 0.07B | P/B | - | EPS next 5Y | 31.74% | ROA | -56.76% | Short Interest | 19.33M | Perf YTD | -4.42% |
| Book/sh | -1.25 | P/C | 7.22 | EPS past 3/5Y | -14.71% -27.07% | ROE | - | 52W High | -31.23% ($88.31) | Perf Year | 5.01% |
| Cash/sh | 8.41 | P/FCF | - | Sales past 3/5Y | -2.36% 9.54% | ROIC | -85.25% | 52W Low | 6.58% ($56.98) | Perf 3Y | 87.38% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -41.03% | Gross Margin | 69.42% | Volatility(W/M) | 3.11% 3.3% | Perf 5Y | 69.4% |
| Dividend TTM | - | EV/Sales | 126.27 | Sales Y/Y TTM | -21.07% | Oper. Margin | -1046.12% | ATR (14) | 2.11 | Perf 10Y | 581.59% |
| Dividend Ex-Date | - | Quick Ratio | 6.66 | EPS Q/Q | -33.78% | Profit Margin | -1321.12% | RSI (14) | 35.08 | Recom | 1.21 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.66 | Sales Q/Q | -57.13% | SMA20 | -3.63% ($63.02) | Beta | 0.46 | Target Price | $109.2 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/4 | SMA50 | -11.55% ($68.66) | Rel Volume | 0.4 | Prev Close | $61.23 |
| Employees | 673 | LT Debt/Eq | - | EPS/Sales Surpr. | 7.87% 62.75% | SMA200 | -13.38% ($70.11) | Avg Volume(3M) | 1.96M | Price | $60.73 |
| IPO | 2004/4/29 | Option/Short | Yes/Yes | Trades | 8704 | Volume | 783,263 | Change | -0.82% |
A U.S. biotech company specializing in the development of cardiovascular drugs that regulate heart muscle function for the treatment of cardiac diseases. Its corporate value is heavily influenced by drug approvals, commercialization progress, clinical trial results, and funding conditions.
Over the past 1 year, on the lower side
31% below its 1-year high.
Traded less than usual. That is 40% of its average volume.
Next earnings report: November 4
9 days to go.
CYTK has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +7.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $12,476. Peers typically go for $1,510.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +69.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 113.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #31 of 594 in the industry
Based on market cap of $8B.
FAQ
What kind of company is CYTK?
CYTK belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CYTK?
The market cap of CYTK is approximately $8.4B, ranking 1,000 within its sector.
What is the 52-week high and low for CYTK?
CYTK has recorded a 52-week high of $88.31 and a low of $56.98.
